Physician profile
Michael Patrick Soos
NPI 1366982241
$4,524.58
in general payments reported to CMS, 2019-2025
31 companies · $1,692 in 2025
The $1,692 reported for 2025 was more than what 81% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $554 · 2020: $146 · 2021: $588 · 2022: $196 · 2023: $618 · 2024: $731 · 2025: $1,692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,041.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,040.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $717.41 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals Lp | $575.05 | 2020-2025 | Lokelma, Andexxa, Wainua |
| E.R. Squibb & Sons, L.L.C. | $341.25 | 2020-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $337.72 | 2019-2025 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $276.77 | 2024-2025 | Lifevest |
| Boston Scientific Corporation | $276.33 | 2019-2024 | Watchman Access System, Watchman Flx, Watchman |
| Pfizer INC. | $215.66 | 2019-2025 | |
| Astellas Pharma US INC | $198.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $194.96 | 2024-2025 | |
| Esperion Therapeutics, INC. | $191.82 | 2024-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $166.54 | 2024-2025 | |
| Allergan, INC. | $156.83 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $116.75 | 2025 | Amvuttra |
| Inari Medical, INC. | $114.50 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Philips North America LLC | $107.80 | 2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $90.86 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.25 | 2019-2025 | Jardiance |
| Medtronic, INC. | $55.18 | 2022 | |
| United Therapeutics Corporation | $47.50 | 2025 | Tyvaso |
| Cvrx, INC. | $42.81 | 2024 | Barostim Neo System |
| Kestra Medical Technology Services, INC. | $31.26 | 2025 | Assure Wcd |
| Actelion Pharmaceuticals US, INC. | $22.84 | 2025 | Opsynvi, Uptravi |
| Kiniksa Pharmaceuticals International, Plc | $22.33 | 2024 | Arcalyst |
| Mallinckrodt Enterprises LLC | $21.16 | 2019 | |
| Alkermes, INC. | $21.12 | 2020 | |
| Stryker Corporation | $20.36 | 2025 | Clottriever Bold Catheter |
| Bridgebio Pharma, INC. | $17.72 | 2025 | Attruby |
| Irhythm Technologies, INC. | $17.70 | 2024 | Zio Xt Patch, Zio Monitor |
| Abiomed | $17.50 | 2025 | |
| Novo Nordisk INC | $12.90 | 2020 | |
| Shire North American Group INC | $12.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Soos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.